Meenakshi Hegde, MD
Department or Service
- Texas Medical Center
- Cell and gene therapy
- Bone Marrow Transplant / Stem Cell Transplant
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Pediatric Hematology Oncology||2012|
|University of Illinois at Chicago, Corner Children's Hospital||residency||Pediatrics||2009|
|All India Institute of Medical Sciences||postgraduate education||Pediatrics||2005|
|Medical College, Mysore, India||medical school||Doctor of Medicine||2003|
|Educational Commission for Foreign Medical Graduates||ecfmg|
|Bangalore Medical College, India||internship/residency||Pediatrics||2005|
Dr. Meenakshi Hegde is a pediatric oncologist engaged in translational research on immunotherapy to improve patient outcomes in high-risk cancer. Her research was the first to demonstrate that a highly heterogeneous landscape of antigen expression in glioblastoma and other solid tumors benefitted from simultaneous targeting of these antigens using a novel bispecific CAR T-cell (TanCAR).
Her current efforts focus on the tumor complex rather than the tumor cell to develop effective T-cell based platform resistant to the inhibitory pathways within the tumor environment and translation of newly developed cellular therapies from the laboratory to clinic through well-designed clinical trials to shape standard of care practices in the field of high-risk cancer therapy. Her clinical interests span adoptive cellular therapy and bone marrow transplant.
Dr. Hegde is a member of the Brain Tumor Research Program at Texas Children's Cancer Center, the Center for Cell and Gene Therapy, and the Bone Marrow / Stem Cell Transplant Program.
She is a board certified physician-specialist in pediatric hematology/oncology and a member of the American Board of Pediatrics.
|American Academy of Pediatrics (AAP)||Member|
|American Association for Cancer Research (AACR)||Member|
|American Society of Bone Marrow Transplant (ASBMT)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|Children's Oncology Group (COG)||Member|
|Karnataka Medical Council, India||Member|
|Society for Immunotherapy of Cancer (SITC)||Member|
Solid tumors enable immune evasion by expressing high-levels of immune-inhibitory ligands that attenuate anti-tumor responses by inducing functional exhaustion and apoptotic death of the activated tumor-antigen specific T cells. Programmed death ligand-1 (PD-L1; B7-H1)/ programmed death protein-1 (PD-1; CD279) immune-checkpoint is a key mediator of this tumor-derived immune-inhibition.
Using a glioma model, we are currently investigating how PD-L1/PD-1 axis can be best manipulated to enhance the anti-tumor efficacy of adoptively transferred chimeric antigen receptor (CAR) T cells.
Our approach will create a broad T-cell engineering platform to modulate tumor derived immune-inhibitory signals for improved cellular therapy of solid tumors.
Schwiesguth Prize by the International Society of Paediatric Oncology (SIOP)
Young Investigator Award by the American Society of Pediatric Hematology-Oncology (ASPHO)